WEAV Stock Alert: Halper Sadeh LLC is Investigating Whether Weave Communications, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Weave Communications, Inc. (NYSE: WEAV) to Francisco Partners for $7.40 per share in cash. Halper Sadeh encourages Weave shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Weave and its board of directors violate.

Business Wire • 17 hours ago

Weave Ranks No. 1 in G2's Fall 2026 Patient Relationship Management Grid Report

LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient engagement and payments platform purpose-built for healthcare practices, has been named the No. 1 Leader in G2's Fall 2026 Grid® Report for Patient Relationship Management (PRM) software, earning the highest satisfaction score and largest market presence of any product in the category. In G2's verified reviews, 94% of users rated Weave 4 or 5 stars, and 96% said the product is headed in the right direction. "Ranking N.

Business Wire • Sep 18, 2026

WEAV Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Weave Communications to Francisco Partners

MONSEY, N.Y., Sept. 15, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Weave Communications, Inc. (NYSE: WEAV) (“Weave”) to Francisco Partners, pursuant to which Weave shareholders will receive $7.40 per share in cash.

GlobeNewsWire • Sep 15, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

GlobeNewsWire • Sep 9, 2026

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. “Regulatory communications are the most knowledge-intensive workflows in all of drug development, and for too long that kn.

Business Wire • Sep 1, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

GlobeNewsWire • Aug 24, 2026

Weave Communications Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Weave Communications, Inc. - WEAV

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Weave Communications, Inc. (NYSE: WEAV) to Francisco Partners. Under the terms of the proposed transaction, shareholders of Weave will receive $7.40 in cash for each share of Weave that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

Business Wire • Aug 21, 2026

Weave's 2026 Pulse Survey Finds Healthcare Practices Are Ready for AI, but 60% Are Still Concerned About Data Privacy

LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient engagement and payments platform purpose-built for healthcare practices, today released its 2026 State of Healthcare Pulse Survey, a survey of 285 owners, office managers, and front desk staff across dental, specialty medical, optometry, and veterinary practices. The findings point to a clear consensus: manual administrative work in disconnected systems is the biggest drag on healthcare practices, and interest in AI i.

Business Wire • Aug 20, 2026

Shareholder Alert: Ademi LLP investigates whether Weave Communications, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, Aug. 19, 2026 /PRNewswire/ -- Ademi LLP is investigating Weave (NYSE: WEAV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Francisco Partners. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Aug 19, 2026

Halper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

GlobeNewsWire • Aug 19, 2026